Infections in the cancer patient. Section 4 (Infections in the immunocompromised host 79)

Détails

ID Serval
serval:BIB_6090F4D58079
Type
Partie de livre
Sous-type
Chapitre: chapitre ou section
Collection
Publications
Institution
Titre
Infections in the cancer patient. Section 4 (Infections in the immunocompromised host 79)
Titre du livre
Infectious Diseases, 4rd Edition, 2010
Auteur⸱e⸱s
O. Marchetti T. Calandra.
Editeur
Edited by J Cohen, WG Powderly. Elsevier Science
Lieu d'édition
Philadelphia and Oxford, USA
Statut éditorial
Publié
Date de publication
2010
Volume
Chapter 73, 804-820.
Langue
anglais
Résumé
In the last decades, advances in early diagnosis and prompt management of febrile neutropenia have markedly improved the outcome of infections in cancer patients. New anticancer chemotherapy and immunomodulating agents have extended the risk and spectrum of opportunistic infections beyond neutropenia in cancer patients. Febrile neutropenia is a medical emergency requiring prompt initiation of empirical therapy with broad-spectrum antibiotics, based on local epidemiology. Low-risk neutropenic patients can be treated as outpatients with a beta-lactam/ ciprofloxacin combination or with moxifloxacin monotherapy. In neutropenic cancer patients with persistent fever, empirical antigungal therapy is recommended. Workup includes reassessment of antibacterial spectrum and therapeutic drug monitoring of blood concentrations, measurement of noninvasive fungal biomarkers, radiologic imaging and microbiologic/ histologic sampling of deep-seated sites of infection.
Création de la notice
11/03/2011 11:29
Dernière modification de la notice
31/01/2020 6:26
Données d'usage